RecruitingNCT05579353

The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression


Sponsor

Jingbo Chen

Enrollment

200 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Summary

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This is a research study — not a treatment trial — looking at biological markers in colon and rectal cancer tissue. Researchers want to understand the role of certain molecules (circ-LRBA and related proteins) that may affect how colorectal cancer grows and spreads. They will collect tissue and fluid samples during surgery. **You may be eligible if...** - You are between 18 and 80 years old - You have a healthy BMI (between 18.5 and 27.9) - You are scheduled to have surgery to remove colon or rectal cancer (such as right colon, left colon, sigmoid colon, or rectal resection) **You may NOT be eligible if...** - You refuse to allow your samples to be collected - You have serious blood clotting problems, liver or kidney disease, or severe heart or lung conditions - You have already received chemotherapy or radiation before surgery - Your cancer has spread to many distant sites in the body Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERnothing

nothing


Locations(1)

The First Affiliated Hospital of Shandong First Medical University

Jinan, Lixia, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05579353